Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction

Authors: Kunihiro Yamaoka, Satoshi Kubo, Koshiro Sonomoto, Keisuke Maeshima, Yoshiya Tanaka

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Tofacitinib, targeting Janus kiase (JAK) has gained attention as anorally available new disease modifying anti-rheumatic drug with high clinical efficacy against rheumatoid arthritis (RA). While the clinical trial has progressed and the wide usage of tofacitinib is conceivable in the near future, the precise mechanism of action in RA patients remains to be solved. …
Metadata
Title
AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
Authors
Kunihiro Yamaoka
Satoshi Kubo
Koshiro Sonomoto
Keisuke Maeshima
Yoshiya Tanaka
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3678

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Poster presentation

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis

Poster presentation

Application of tetraspanin CD81 RNAi for diagnosis and therapy of rheumatoid arthritis (RA)

Oral presentation

Innate and adaptive immune responses to dead and dying cells

Oral presentation

Regulation of inflammatory immune responses leading to the development of bone destructive autoimmune disease rheumatoid arthritis by IL-27

Oral presentation

Overview of biotherapy in rheumatoid arthritis (RA)

Poster presentation

Stimulation of bone formation in cortical bone of the mice treated with a novel bone anabolic peptide with osteoclastogenesis inhibitory activity
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits